Rapport Therapeutics shares are up today after good news from their Phase 2 trial for RAP-219.

Oct 20, 2026, 9:48 AM ETTrialRead the original at Benzinga

Good for RAPP

Rapport's RAP-219 improved the main mania score by 3.1 points against placebo, and it also met a second symptom measure. Side-effect rates were similar, but the result came from a 3-week study, with 2 larger studies not expected until 2027.

RAPP · Rapport Therapeutics Inc.

AI read · Good for RAPP

The AI's read

These results make RAP-219 a stronger candidate for later testing and add bipolar mania to Rapport's existing epilepsy program. The same drug may have uses in both conditions. The main symptom score improved by 3.1 points against placebo over 3 weeks. Rapport plans 2 larger studies in 2027, so those studies still need to confirm the finding.

Get alerts for RAPP

Follow Rapport Therapeutics Inc. (RAPP) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for RAPP

Free on the App Store and Google Play, or on the web.